| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/22/2007 | WO2007019867A1 Novel 2,3-dihydroindole compounds |
| 02/22/2007 | WO2006134486A3 Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists |
| 02/22/2007 | WO2006122777A3 Use of 2,5-disubstituted thiazol-4-one derivatives in drugs |
| 02/22/2007 | WO2006116218A8 Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride |
| 02/22/2007 | WO2006112744A3 Drug composition with analgesic, anti-inflammatory and decongestive activity |
| 02/22/2007 | WO2006107948A9 Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents |
| 02/22/2007 | WO2006103261A3 Inhibitors of neurotrypsin and determination thereof |
| 02/22/2007 | WO2006099351A3 Hydrocodone polymorphs |
| 02/22/2007 | WO2006098834A3 Crystalline forms of ziprasidone mesylate |
| 02/22/2007 | WO2006097263A3 Orally used compatible solute containing agents |
| 02/22/2007 | WO2006091703A3 Multimediator 5-ht6 receptor antagonists, and uses related thereto |
| 02/22/2007 | WO2006081431A3 Compounds for treating inflammatory and demyelinating diseases |
| 02/22/2007 | WO2006069202A3 Compositions comprising anti-igf-i receptor antibodies and methods for obtaining said antibodies |
| 02/22/2007 | WO2006036278A3 THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF |
| 02/22/2007 | WO2006002119A3 Kinase inhibitors for treating cancers |
| 02/22/2007 | US20070043122 Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders |
| 02/22/2007 | US20070043116 Method for preventing and/or treating neurodegenerative diseases |
| 02/22/2007 | US20070043114 Nerve regeneration promoters |
| 02/22/2007 | US20070043105 Preventive for cerebal stroke recurrence |
| 02/22/2007 | US20070043095 have a good affinity for certain subtypes of somatostatin receptors and have useful pharmacological properties |
| 02/22/2007 | US20070043079 Heterocyclic compound containing nitrogen atom and use thereof |
| 02/22/2007 | US20070043075 2-Methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts |
| 02/22/2007 | US20070043073 Imidazopyridine-derivatives as inductible no-synthase inhibitors |
| 02/22/2007 | US20070043064 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines |
| 02/22/2007 | US20070043056 5-Substituted-2-arylpyrazines |
| 02/22/2007 | US20070043048 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents |
| 02/22/2007 | US20070043038 Indolone-acetamide derivatives, processes for preparing them and their uses |
| 02/22/2007 | US20070043031 Non-amide nonanes |
| 02/22/2007 | US20070043026 Dopamine receptor modulators as antipsychotic agents |
| 02/22/2007 | US20070042999 Phosphate derivatives of pharmaceutical products |
| 02/22/2007 | US20070042964 Compositions and methods for modulating connexin hemichannels |
| 02/22/2007 | US20070042963 Therapeutic peptides |
| 02/22/2007 | US20070042935 Quinazolinone-derivatives and their use for preparation of pharmaceutical compositions having parp enzyme inhibitory effect |
| 02/22/2007 | US20070042446 Drug screening; for inhibiting apoptosis in mammalian cells; zinc finger domains; consensus sequences; genetic engineering; for treating AIDS, alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, autoimmune diseases |
| 02/22/2007 | US20070042416 Dendritic Enriched Secreted Lymphocyte Activation Molecule |
| 02/22/2007 | US20070042056 Anti-stress agent |
| 02/22/2007 | US20070041996 Aromatase activating agent |
| 02/22/2007 | US20070041947 Use of a lentiviral vector in the treatment of pain |
| 02/22/2007 | US20070041945 Novel method for down-regulation of amyloid |
| 02/22/2007 | DE202006019112U1 Vegetable based suspension, useful to treat e.g. neurodegenerative disease and skin diseases, comprises hibiscus blossom, dried Saxifraga species, dried Solidago virgaurea, dried Salvia officinalis and dried Opuntia ficus indica, in vodka |
| 02/22/2007 | DE202006018834U1 Zusammensetzung mit einem Getreidemahlerzeugnis Composition with a grain milling product |
| 02/22/2007 | DE202006002547U9 Kombinationen von abwendenden Maßnahmen bei Alzheimer und anderen Demenzen Combinations of averting measures in Alzheimer's and other dementias |
| 02/22/2007 | DE102005038831A1 New N-acylalkoxycarbonyl-piperidine derivatives, useful as CGRP antagonists, for treating e.g. headaches, cardiovascular disease, skin disorders, morphine tolerance, and inflammatory diseases such as osteoarthritis and allergic rhinitis |
| 02/22/2007 | DE102005033943A1 Nicht-ausspuckbarer, oraler, schnell-zerfallender Film für ein Neuroleptikum Non-ausspuckbarer, oral, fast-disintegrating film for a neuroleptic |
| 02/22/2007 | DE102005033942A1 Nicht-ausspuckbarer, oraler, schnell-zerfallender Film für Antiemetikum oder Antimigränemittel Non-ausspuckbarer, oral, fast-disintegrating film for anti-emetic or anti-migraine agents |
| 02/22/2007 | CA2619725A1 Single chain antibodies against beta-amyloid peptide |
| 02/22/2007 | CA2619721A1 Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease |
| 02/22/2007 | CA2619480A1 Method of using potassium channel inhibiting compounds |
| 02/22/2007 | CA2619462A1 Phosphodiesterase 10 inhibitors |
| 02/22/2007 | CA2619223A1 Fluoro substituted 2-oxo azepan derivatives |
| 02/22/2007 | CA2619217A1 Neurorestoration with r(+) pramipexole |
| 02/22/2007 | CA2619010A1 Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
| 02/22/2007 | CA2618834A1 Selected cgrp antagonists, methods for the production thereof and their use as medicaments |
| 02/22/2007 | CA2618653A1 Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder |
| 02/22/2007 | CA2618568A1 Thiazolyl piperidine derivatives useful as h3 receptor modulators |
| 02/22/2007 | CA2618508A1 Truncated memapsin 2 for use for treating alzheimer's disease |
| 02/22/2007 | CA2618212A1 Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use of same |
| 02/22/2007 | CA2618110A1 Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics |
| 02/22/2007 | CA2618057A1 Modulators of cystic fibrosis transmembrane conductance regulator |
| 02/22/2007 | CA2617828A1 Derivatives of 5-pyridinyl-1-azabicyclo[3.2.1]octane, preparation methodthereof and use of same in |
| 02/22/2007 | CA2617107A1 Olanzapine analogs and methods of use thereof |
| 02/22/2007 | CA2616318A1 Acetylenic piperazines as metabotropic glutamate receptor antagonists |
| 02/22/2007 | CA2616308A1 Bicyclic piperazines as metabotropic glutamate receptor antagonists |
| 02/22/2007 | CA2616307A1 Substituted piperazines as metabotropic glutamate receptor antagonists |
| 02/22/2007 | CA2615121A1 Method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion |
| 02/21/2007 | EP1754707A2 Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes |
| 02/21/2007 | EP1754705A2 Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders |
| 02/21/2007 | EP1754703A2 N-Heterocyclic derivatives as nos inhibitors |
| 02/21/2007 | EP1754491A1 Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist |
| 02/21/2007 | EP1754485A1 Remedy for neurodegenerative diseases |
| 02/21/2007 | EP1754480A2 Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 02/21/2007 | EP1754479A1 Capsule stable against mastication |
| 02/21/2007 | EP1754475A1 Use of C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 02/21/2007 | EP1754474A1 Use of S-Clenbuterol |
| 02/21/2007 | EP1754469A1 Injectable suspensions having improved injectability properties |
| 02/21/2007 | EP1753760A1 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide |
| 02/21/2007 | EP1753757A1 Substituted 2,5-diaminomethyl-1h-pyrroles |
| 02/21/2007 | EP1753743A1 Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
| 02/21/2007 | EP1753738A1 Pyrrole compounds as inibitors of erk protein kinase, synthesis thereof and intermediates thereto |
| 02/21/2007 | EP1753736A2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/21/2007 | EP1753725A1 Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics |
| 02/21/2007 | EP1753719A1 Substituted pyrrolidine-2-ones |
| 02/21/2007 | EP1753718A1 3-amino-2-phenylpyrrolidine derivatives |
| 02/21/2007 | EP1753511A2 Treating depressive disorders with carbonic anhydrase activators |
| 02/21/2007 | EP1753460A2 Combination of atypical antipsychotics and 5-ht1b receptor antagonists |
| 02/21/2007 | EP1753439A2 Use of umbilical cord blood stem cells to treat ischemic event |
| 02/21/2007 | EP1753430A2 Combination of atomoxetine and a 5ht1a receptor agonist for treating adhd and other disorders |
| 02/21/2007 | EP1753429A1 Modulators of muscarinic receptors |
| 02/21/2007 | EP1753415A2 Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| 02/21/2007 | EP1753414A1 Novel use of peptide compounds for treating dyskinesia |
| 02/21/2007 | EP1581517B1 Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| 02/21/2007 | EP1567488B1 Hydroxyethylamine derivatives for the treatment of alzheimer's disease |
| 02/21/2007 | EP1551798B1 Novel sulphones for inhibition of gamma secretase |
| 02/21/2007 | EP1529047B1 New purine derivatives |
| 02/21/2007 | EP1519726B1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 02/21/2007 | EP1511727B1 Aromatic sulfones and their medical use |
| 02/21/2007 | EP1501508B1 Inhibitors of histone deacetylase |
| 02/21/2007 | EP1458690B1 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists |
| 02/21/2007 | EP1406857B1 Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds |
| 02/21/2007 | EP1355905B1 Pyrazole compounds useful as protein kinase inhibitors |